Adavivint manufacturers
- Adavivint
-
- $36.00
-
2026-05-11
- CAS:1467093-03-3
- Purity: 99.54%
- Supply Ability: 10g
|
| | Adavivint Basic information |
| Product Name: | Adavivint | | Synonyms: | N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide;CPD1633;SM-04690;SM 04690;SM04690;Butanamide, N-[5-[3-[7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl]-3-pyridinyl]-3-methyl-;Adavivint;Wnt,SM 04690,Adavivint,SM04690,Lorecivivint,SM-04690,inhibit,Inhibitor;Adavivint, 10 mM in DMSO;Adavivint (SM04690) ，S8761 | | CAS: | 1467093-03-3 | | MF: | C29H24FN7O | | MW: | 505.55 | | EINECS: | | | Product Categories: | | | Mol File: | 1467093-03-3.mol |  |
| | Adavivint Chemical Properties |
| density | 1.365±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO:27.5(Max Conc. mg/mL);54.4(Max Conc. mM) | | pka | 7.75±0.40(Predicted) | | form | Solid | | color | Light yellow to gray | | InChIKey | AQDWDWAYVBQMAM-UHFFFAOYSA-N | | SMILES | C(NC1=CC(C2C=CC3=C(C=2)C(C2=NC4C(C5=CC=CC(F)=C5)=CN=CC=4N2)=NN3)=CN=C1)(=O)CC(C)C |
| | Adavivint Usage And Synthesis |
| Uses | Adavivint is an intra-articular potential disease-modifying osteoarthritis drug. | | Biological Activity | Adavivint (SM04690) is a potent canonical Wnt signaling pathway inhibitor with EC50 of 19.5 nM for TCF/LEF reporter gene. It was more potent than other known Wnt inhibitors in multiple cellular experiments. | | in vitro | Treatment of bone marrow-derived human mesenchymal stem cells (CD29+, CD44+ CD166+ CD105+ CD45-) with SM04690 induced a concentration-dependent decrease in Wnt pathway gene expression (ASCL1, LEF1, TCF7L2, TCF7 , C-262 MYC and AXIN2). Selective activation of Wnt signaling pathway with Wnt3a or GSK3β inhibitor CHIR-99021, in IEC6 (intestinal stem cells sensitive to Wnt activation), M04690 can inhibit the expression of AXIN2 and LGR5; in hMSCs, inhibit the expression of AXIN2, TCF7 and LEF1 Express. It has minimal effects on non-canonical Wnt signaling and BMP signaling. In vitro, SM04690 protects chondrocytes from metabolic breakdown. | | in vivo | Intra-articular injection of Adavivint promotes cartilage growth and improves joint health in a rat model of knee osteoarthritis. In vivo, it reduces cartilage breakdown. | | target |
| | Adavivint Preparation Products And Raw materials |
|
|
Tag:Adavivint(1467093-03-3)
Related Product Information
|
|
Barium carbonate
3--Phenyl-N-(2,2,2-trichloro-1-((((4-chlorophenyl)amino)carbonothioyl)amino)ethyl)acrylamide
BAY 299
T-26c
AZD-7594
4-[4-(1-methyl-1H-pyrazol-4-yl)-1-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-1H-imidazol-5-yl]-benzonitrile
ABBV-744
Zofluza intermediate
RGX-104 HCl
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|